Immedica Pharma Ab
7 products tracked · names used in filings: Immedica Pharma Ab, Immedica Pharma AB
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 23 Feb 2026🇺🇸 FDA approval
FDA approves Loargys (pegzilarginase-nbln), a new medicine
Immedica Pharma Ab; BLA761211; New biologic, Priority review; injectable · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Loargys pegzilarginase-nbln | Approved | 2026-02-23 |
| 🇪🇺 | Loargys pegzilarginase | Authorised | 2023-12-15 |
| 🇪🇺 | Efmody hydrocortisone | Authorised | 2021-05-27 |
| 🇪🇺 | Alkindi hydrocortisone | Authorised | 2018-02-09 |
| 🇪🇺 | Ravicti glycerol phenylbutyrate | Authorised | 2015-11-26 |
| 🇪🇺 | Ammonaps sodium phenylbutyrate | Authorised | 1999-12-07 |
| 🇪🇺 | Emadine emedastine | Authorised | 1999-01-27 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.